Additional file 4: Figure S2. of Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

  • Iain C. Macdougall (Contributor)
  • Andreas H. Bock (Contributor)
  • Fernando Carrera (Contributor)
  • Kai-Uwe Eckardt (Contributor)
  • Carlo Gaillard (Contributor)
  • David Van Wyck (Contributor)
  • Yvonne Meier (Contributor)
  • Sylvain Larroque (Contributor)
  • Simon D Roger (Contributor)



(a) Ferritin and (b) transferrin saturation (TSAT) for patients with eGFR values at baseline and month 12 who did or did not receive alternative anemia therapy or permanently discontinued study therapy before month 12. BL, baseline; FCM, ferric carboxymaltose. (ZIP 456Â kb)
Date made available17-Jan-2017
PublisherUniversity of Groningen

Cite this